Ozempic can be associated with eye problems, but temporary blurred vision, diabetic retinopathy complications, and NAION are different concerns. They affect different parts of the eye, have different evidence behind them, and should not be grouped into a single “Ozempic blindness” statistic.
On November 9, 2026, the FDA required new warnings about a potential increased risk of the rare optic nerve condition NAION across GLP-1 receptor agonist medicines, including Ozempic. Older articles may not reflect that development.
If you have sudden loss of vision, a new missing area of vision, or rapidly worsening eyesight, seek urgent medical assessment now. Painless vision loss is still urgent. A sudden shower of floaters, flashes of light, or a curtain-like shadow also calls for an eye doctor or emergency room right away; these can be retinal detachment symptoms. You do not need to establish whether Ozempic caused a change before getting help.
Three eye concerns that need separate explanations
| Concern | What is happening | What the evidence means |
|---|---|---|
| Temporary glucose-related blur | Changes in blood glucose can alter fluid levels in the eye's focusing tissues | This can happen during changes in diabetes treatment; blur alone cannot identify the cause |
| Diabetic retinopathy complications | Diabetes damages blood vessels in the retina, the light-sensitive tissue at the back of the eye | Ozempic's U.S. label includes a warning, with particular attention to people who already have retinopathy |
| NAION | Reduced blood flow injures the front of the optic nerve, which carries visual signals to the brain | A rare, potentially permanent vision-loss condition addressed in the FDA's November 2026 safety action |
These categories overlap in how a person might describe them. “Everything looks blurry” is a symptom, not a diagnosis. An eye examination helps determine which tissue is involved and whether treatment is needed.
Can blurred vision be temporary when glucose changes?
Yes. The National Institute of Diabetes and Digestive and Kidney Diseases explains that people sometimes experience blurred vision for days or weeks when their diabetes care or medicines change. High glucose can change fluid levels or cause swelling in the tissues used for focusing. That particular type of blur improves as glucose gets closer to normal.
This is different from damage to retinal blood vessels or the optic nerve. It also does not mean that any blur after starting Ozempic is a harmless adjustment. Contact your healthcare provider about new vision changes, as the Ozempic Medication Guide instructs. Sudden or rapidly worsening symptoms belong in urgent assessment, rather than a trial of waiting for glucose to settle.
Timing helps a clinician investigate a symptom; it cannot settle the explanation by itself. A change beginning after a new prescription may be related to treatment, an existing eye condition, or another problem occurring at the same time.
What does the retinopathy warning actually say?
Diabetic retinopathy is disease of the retina's blood vessels. It may progress without noticeable symptoms, and complications can threaten sight. Diabetic macular edema—swelling in the central area of the retina used for detailed vision—is another diabetes-related retinal problem. Neither is the same diagnosis as NAION.
In SUSTAIN-6, 3,297 people with type 2 diabetes were assigned to weekly semaglutide or placebo alongside standard care for 104 weeks. This was a population at high cardiovascular risk. Retinopathy complications occurred in 50 of 1,648 semaglutide participants (3.0%), compared with 29 of 1,649 placebo participants (1.8%).
That is an absolute difference of 1.2 percentage points in this trial. The outcome included bleeding into the eye, diabetes-related blindness, or a need for retinal laser treatment or medication injected into the eye. It was not a measure of all temporary blur, and it does not mean that 3% of Ozempic users become blind.
The U.S. prescribing information further separates participants by their starting eye history:
| Retinopathy history at baseline | Ozempic | Placebo |
|---|---|---|
| Known diabetic retinopathy | 8.2% | 5.2% |
| No known diabetic retinopathy | 0.7% | 0.4% |
These are complication percentages within the respective subgroups of the two-year trial, not annual rates or estimates for people without diabetes. The label calls for monitoring progression in patients with a history of diabetic retinopathy.
Why can improving glucose initially worsen retinopathy?
Rapid improvement in glucose control can temporarily worsen existing diabetic retinopathy. A post hoc analysis of SUSTAIN-6 suggested that much of the observed difference could be explained by large, rapid HbA1c reductions during the first 16 weeks, particularly in people with pre-existing retinopathy, poor starting glucose control, and insulin treatment.
That is a plausible explanation supported by an additional analysis, rather than proof that every event had the same mechanism. Nor does “temporary worsening” promise that an individual complication will reverse without treatment. The practical implication is to coordinate glucose treatment and eye follow-up, especially when retinopathy is already present—not to deliberately keep glucose high or change a dose yourself.
What is known about Ozempic and NAION?
NAION stands for non-arteritic anterior ischemic optic neuropathy. Unlike retinopathy, it affects the optic nerve. It can cause sudden, painless loss of sight, often in one eye, and the loss can be permanent.
A Danish–Norwegian registry study compared people with type 2 diabetes starting semaglutide with those starting SGLT-2 inhibitors, another class of diabetes medicine. It used Danish records from 2018–2024 and Norwegian records from 2018–2022, including 61,377 semaglutide initiators and 32 NAION events among them.
The pooled adjusted hazard ratio was 2.81, with a 95% confidence interval of 1.67–4.75. The estimated absolute rate difference was 1.41 additional cases per 10,000 person-years, with a confidence interval of 0.53–2.29. Person-years combine the time people were followed: 10,000 people followed for one year contribute 10,000 person-years.
The relative increase matters, but so does the small absolute difference. This observational comparison supports an association; differences between the treatment groups may still influence the estimate. It is not a personal risk calculation, and its type 2 diabetes population should not be silently recast as everyone using semaglutide for weight management.
Reports submitted after a medicine reaches the market serve a different purpose. They can flag a problem worth investigating, but the number of reports is not a denominator of everyone taking the medicine. They cannot, by themselves, establish how frequently Ozempic causes a condition.
U.S. and European instructions are not identical
The FDA's November 2026 communication tells patients with symptoms such as sudden painless loss of sight, missing vision, altered colors, or reduced central sharpness to contact a healthcare professional right away. Suspected NAION needs prompt ophthalmology evaluation. After a NAION event, patients should discuss continuing or stopping treatment; clinicians should consider discontinuation unless treatment benefits clearly outweigh the risk.
The European Medicines Agency's June 2025 assessment classified NAION as a very rare semaglutide side effect, potentially affecting up to 1 in 10,000 people. Its instruction is to contact a doctor without delay for sudden vision loss or rapidly worsening eyesight, and to stop semaglutide if NAION is confirmed. That European frequency category is not the same measure as a study's annual incidence rate.
These are jurisdiction-specific instructions to review with your U.S. care team.
What to arrange before the next routine visit
If you have diabetes, ask whether your dilated eye examination is up to date. Existing retinopathy needs its own follow-up schedule; feeling that your sight is normal does not rule out retinal disease. Tell both your prescriber and eye doctor about Ozempic, any previous retinopathy or NAION, and recent changes in glucose treatment.
Three questions can make that conversation more useful:
- What is my current retinal diagnosis, if any, and does it change my follow-up schedule?
- How will my diabetes treatment and eye care be coordinated as glucose improves?
- Where should I go immediately if my sight changes suddenly?
For a new symptom, describe when it started, whether one or both eyes seem affected, and whether it involves blur, missing vision, flashes, floaters, or a shadow. Share your medication list and recent treatment changes. Gathering those details should not delay urgent care.
The evidence discussed here does not establish a home routine that prevents semaglutide-associated NAION. An app, a symptom log, or a scheduled eye appointment cannot clear an urgent symptom. The useful distinction is between arranging appropriate follow-up while you feel well and getting immediate help when vision changes demand it.

About the author
Maya Lee
Glowise Senior GLP-1 Content Editor
Maya Lee is a Glowise Health Content Editor. Her guides turn product records, authoritative sources, and everyday organization questions into clear, practical GLP-1 information.
She helps readers ask better questions and keep the details relevant to a care conversation together.
See more Glowise on Google
Add Glowise as a preferred source to find our GLP-1 guides more easily in Google Search.

